Cancer: Still a contraindication for allergen immunotherapy? Specific immunotherapy and cancer
Por:
El-Qutob, D, Letran, A, Matheu, V and Fernandez-Caldas, E
Publicada:
1 oct 2021
Ahead of Print:
1 oct 2021
Resumen:
Allergen immunotherapy (AIT) is currently more than 100 years old. It is considered an evidencebased efficacious immune therapeutical treatment. It is at this time the only causative treatment for allergic respiratory and venom allergic diseases. Though clinical indications for AIT are well established, clinical contraindications to AIT differ among several guidelines. Regarding malignant neoplasia, traditionally, it has been considered as a relative or absolute contraindication with the concern that AIT might stimulate tumour growth even though pathogenic impact of AIT in cancer is not well understood. Furthermore, this contraindication is often based on observational case series, or case reports, with little real evidence-based data. Therefore, should cancer still be contemplated as an absolute contraindication for AIT? Keywords: Cancer, Neoplasm, Specific immunotherapy, Allergen, Contraindication
Filiaciones:
:
Univ Hosp La Plana, Allergy Unit, Vila Real, Spain
Letran, A:
Hosp HLA Jerez Puerta Sur, Allergy Unit, Cadiz, Spain
Matheu, V:
Univ Hosp Canarias, Serv Allergol, Tenerife, Spain
Fernandez-Caldas, E:
Inmunotek SL, Madrid, Spain
Univ S Florida, Coll Med, Tampa, FL 33620 USA
Green Published, gold
|